The drug, aducanumab, marketed under the brand name Aduhelm, would be the first medication aimed at attacking the disease mechanism in Alzheimer’s.
As a result of this decision, three of the FDA’s advisers have resigned from the expert committee that overwhelmingly advised against approving the drug.
determined that, given the limited proof aducanumab does any good, the highest price that could be justified for a year’s treatment lies between $2,560 and $4,850.
There is also the reality that the drug has to be infused, requiring monthly hospital visits, followed by MRI scans to track the results.